Invasive candidiasis

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly discovered yeast that causes serious blood infections, particularly in vulnerable patients like premature infants and those with cancer. Though still rare, cases are increasingly appearing in tropical regions with documented hospital outbreaks. While the infection has a better survival rate than related species, it resists several common antifungal drugs, making treatment challenging and requiring careful use of remaining effective medications.

Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives

mycolabadmin

Invasive candidiasis is a serious fungal infection affecting critically ill patients in hospitals. Current testing methods like blood cultures are slow and sometimes miss the infection. Researchers are developing faster diagnostic tests using DNA detection and biomarkers that can identify infections within hours instead of days, allowing doctors to start treatment sooner and save more lives.

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal medication called rezafungin to treat a serious eye infection caused by the fungus Candida albicans. Using rabbit models, they found that rezafungin was much more effective than two other antifungal drugs at clearing the infection from the eye and preventing damage to vision. The drug’s ability to work for longer periods with less frequent dosing makes it a promising candidate for treating this devastating infection in patients.

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous fungus that can cause fluid buildup around the lungs (empyema), particularly in transplant patients. Unlike common fungal infections that respond to fluconazole, this species is naturally resistant to this drug, making it harder to treat. The fungus forms protective biofilms that shield it from treatment, requiring combination antifungal medications and sometimes surgery to drain the fluid and remove infected tissue for successful recovery.

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development

mycolabadmin

Researchers developed a test using synthetic sugar molecules found on Candida yeast to detect antibodies in blood from infected patients and mice. They discovered that the immune system produces different antibodies at different stages of infection, starting with antibodies against certain sugars and later focusing on others. The study identified three specific sugar structures that could be used to create simple blood tests to diagnose Candida infections and potentially develop vaccines to prevent these serious fungal infections.

Changing Climate, Changing Candida: Environmental and Social Pressures on Invasive Candidiasis and Antifungal Resistance in Latin America

mycolabadmin

Invasive fungal infections caused by Candida yeasts are becoming more serious in Latin America, with drug-resistant strains spreading rapidly in hospitals. The problem is worsened by climate change and overuse of antifungal medicines in agriculture, which help resistant fungi survive and spread. Many hospitals in the region lack modern diagnostic tools to quickly identify the specific type of infection, delaying treatment. The authors recommend a comprehensive approach combining better environmental monitoring, smarter use of antifungal drugs, improved diagnostic access, and coordinated public health efforts across the region.

Investigating the Increasing Azole Resistance in Candida Infections Among Critically Ill Patients: Experience From a Tertiary-Level Setup in North India

mycolabadmin

This study tracked the increase in drug-resistant yeast infections in hospitalized patients in India from 2023 to 2025. The researchers found that common antifungal medications like fluconazole are becoming less effective, with resistance rates nearly doubling over the study period. The good news is that newer antifungal drugs called echinocandins remained highly effective. The findings highlight the need for better infection control measures and more careful use of antifungal medications.

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005–2025)

mycolabadmin

Invasive candidiasis, a serious fungal blood infection caused by Candida species, is a major health crisis in Latin America and the Caribbean with death rates reaching 60% in vulnerable populations. The disease is worsening in areas affected by armed conflict, violence, and displacement where poor living conditions, overcrowding, malnutrition, and lack of healthcare create ideal conditions for the infection to develop and spread. Antifungal drugs are often unavailable or too expensive, and drug-resistant strains of Candida are becoming increasingly common, making treatment extremely challenging in these regions.

Changing Climate, Changing Candida: Environmental and Social Pressures on Invasive Candidiasis and Antifungal Resistance in Latin America

mycolabadmin

Invasive fungal infections caused by Candida species are becoming increasingly common and dangerous in Latin American hospitals, with newer strains showing resistance to multiple antifungal drugs. Rising temperatures from climate change and widespread use of fungicides in agriculture appear to be selecting for these resistant fungi. Most hospitals in the region lack advanced diagnostic tools to quickly identify which fungal strain is causing infection, leading to delayed and sometimes inappropriate treatment. Implementing better diagnostic access, stricter antifungal use policies, and coordinated surveillance programs across the region could help control this growing public health problem.

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous yeast that causes a serious lung infection called empyema, where pus collects around the lungs. This infection is particularly difficult to treat because the yeast is resistant to common antifungal drugs like fluconazole and can form protective biofilms. This systematic review identified only ten cases of this rare infection in the medical literature, showing how uncommon but serious it is, and found that patients need aggressive treatment with multiple antifungal medications combined with surgical drainage to survive.

Research Topic: Invasive candidiasis